Plain-Language Summaries for Blood and Cancer Patient Letters
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether simplified, easy-to-read versions of your hospital discharge letters help you better understand your diagnosis and treatment plan. Researchers will ask you questions about the letter to see if the plain-language version works better than the standard medical version.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are currently a patient in the Hematology/Oncology (blood cancer) department at Klinikum rechts der Isar hospital in Munich, Germany
- You received a discharge letter from the hospital as part of your regular care
- You are mentally able to understand and answer questions about your discharge letter on your own
- You can read and sign an informed consent form showing you want to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if an AI-generated plain language summary is as good as a human-written one for women with breast cancer. It compares how patients understand information about their treatment options.
This study looks at how T-cells (a type of immune cell) work in people with certain blood cancers (B-cell lymphoma or multiple myeloma) compared to healthy volunteers. The goal is to learn more about the immune system in these cancers, which may help improve future treatments.
This trial tests if a special tool can help adults aged 60 and older who are newly visiting a blood cancer or bone marrow transplant clinic understand their options and make decisions that fit their needs.
This study compares two ways to read your medical notes: the original doctor's version and a simplified AI summary. Researchers want to see which format helps patients better understand their care and medical information.
This study collects extra blood samples during your routine care to look for markers that might help predict how well cancer treatments work and how long people live. Participating involves no extra procedures beyond what you already need.
This study tests an approach to help people with certain blood cancers and their main caregiver plan ahead and communicate more clearly about end-of-life care. It may help patients feel more supported and better prepared for difficult decisions.
Hear when a new Oncologic Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.